(Alliance News) - Faron Pharmaceuticals Oy on Thursday said it has amended a trial for its Traumakine medication after receiving feedback from the US Food & Drug Administration.
The medication, designed to prevent acute respiratory distress syndrome, where a patient's lungs become very inflamed as a result of a injury or an infection.
Traumakine works by using the interferon-beta protein, found in the human body, to restore the endothelial barrier, found in the lining of blood vessels.
According to the FDA, studies on Traumakine should not use overlapping steroids which "block the desired therapeutic effect" of the drug.
Faron said: "Faron will continue to work in close collaboration with the FDA to achieve final approval for the next study."
The company also noted a report by the World Health Organisation which stated steroids should not be used on patients infected by the coronavirus.
Faron explained that steroids may block production of interferon-beta, which will be detrimental to patients with the virus.
China's coronavirus crisis deepened on Thursday with the death toll reaching 563.
Faron shares were 0.4% lower at 225.00p each in London on Thursday afternoon.
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Faron Pharma (FARN)